Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review
Mengyu Tao,1,2 Jiejun Cheng,3 Xia Wu1,2 1Department of Obstetrics & Gynecology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, People’s Republic of China; 2Shanghai Key Laboratory of Gynecologic Oncology, Shanghai 200127, People’s Repub...
Main Authors: | Tao M, Cheng J, Wu X |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-12-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/niraparib-as-maintenance-therapy-in-germline-atm-mutated-and-somatic-b-peer-reviewed-article-OTT |
Similar Items
-
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
by: Jiang X, et al.
Published: (2019-05-01) -
Rapid and temporary improvement of depression and anxiety observed following niraparib administration: a case report
by: Benjamin E. Jewett, et al.
Published: (2020-04-01) -
Rapid and Temporary Improvement of Depression and Anxiety Observed Following Niraparib Administration: A Case Report
by: Jewett, Benjamin E., et al.
Published: (2020) -
Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer
by: Jinyu Meng, et al.
Published: (2021-10-01) -
The characteristics of determination of BRCA1 and BRCA2 mutations in serous ovarian cancer
by: I A Demidova
Published: (2017-01-01)